SEBI Reg. Investment Advisor

Download App

Help Center Subscribe

Recent:

Top Pharma Companies in India by Market Cap

BSE Sensex 76831.75
4.03 (-0.01%)

Filter

Top Pharma Companies in India as on Jul-2026 | 5 Star Rated Stocks Undervalued Stocks Fair Valued Stocks Uptrend Stocks

Filter

	Company Name	DeciZen	Market cap (Rs. Cr.)	CMP (Change %)	Latest P/E	Latest P/BV	5Y Sales Gr.(%)	5Y Profit Gr.(%)
1	Nectar Lifesciences Ltd.	Q V PT	202 Small Cap	10.06 (-3.45%)	N/A	0.35	-6.71	-232.05	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
2	Health X Platform Ltd.	Q V PT	985 Small Cap	309.75 (0.00%)	N/A	3.64	109.54	-201.92	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
3	Indoco Remedies Ltd.	Q V+ PT	2,287 Small Cap	247.75 (0.00%)	N/A	2.08	6.54	-182.78	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
4	Unichem Laboratories Ltd.	Q V PT	3,826 Small Cap	543.45 (0.00%)	24.07	1.46	4.67	-173.72	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
5	Solara Active Pharma Sciences Ltd.	Q V PT	2,439 Small Cap	506.80 (0.24%)	N/A	1.91	-0.58	-134.64	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
6	Suraksha Diagnostic Ltd.	Q V PT	1,300 Small Cap	249.80 (0.04%)	40.4	5.31	9.86	-51.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
7	Jubilant Pharmova Ltd.	Q V+ PT	15,582 Small Cap	978.25 (0.00%)	783	6.74	-24.99	-38.93	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
8	Dishman Carbogen Amcis Ltd.	Q V+ PT	2,922 Small Cap	186.35 (0.00%)	29.98	0.44	5.82	-33.01	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
9	Biocon Ltd.	Q V PT	71,063 Mid Cap	437.55 (0.34%)	1910.29	2.6	2.96	-18.61	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
10	Shilpa Medicare Ltd.	Q V+ PT	12,144 Small Cap	620.90 (0.00%)	49.91	4.69	7.22	-12.54	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
11	Alembic Pharmaceuticals Ltd.	Q V+ PT	16,009 Small Cap	814.45 (0.00%)	23.73	2.82	6.37	-8.79	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
12	Sanofi India Ltd.	Q V PT	7,760 Small Cap	3,369.25 (0.00%)	25.05	9.95	-8.74	-7.50	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
13	Piramal Pharma Ltd.	Q V PT	25,569 Small Cap	191.85 (-0.10%)	36.53	3.17	10.23	-6.64	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
14	Granules India Ltd.	Q V+ PT	20,878 Small Cap	844.95 (0.28%)	51.82	5.09	2.07	-5.88	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
15	Cohance Lifesciences Ltd.	Q V+ PT	16,444 Small Cap	426.45 (-0.78%)	91.75	4.2	7.51	-3.15	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
16	Laurus Labs Ltd.	Q V+ PT	92,623 Mid Cap	1,714.25 (0.00%)	84.7	16.43	7.19	-2.25	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
17	Tarsons Products Ltd.	Q V PT	1,707 Small Cap	321.55 (0.20%)	75.35	2.53	12.30	-1.67	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
18	Hikal Ltd.	Q V+ PT	2,739 Small Cap	223.95 (0.83%)	N/A	2.28	4.29	-1.50	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
19	Strides Pharma Science Ltd.	Q V+ PT	9,623 Small Cap	1,044 (0.00%)	52.4	2.93	3.25	-0.75	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
20	Aurobindo Pharma Ltd.	Q V+ PT	89,115 Mid Cap	1,542.65 (-0.40%)	36.9	3.92	-3.95	-0.50	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
21	Fermenta Biotech Ltd.	Q V PT	1,307 Small Cap	433 (-2.48%)	20.33	3.11	3.85	-0.38	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
22	Onesource Specialty Pharma Ltd.	Q V PT	19,375 Small Cap	1,699.60 (0.59%)	406.87	3.23	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
23	Aarti Pharmalabs Ltd.	Q V+ PT	6,217 Small Cap	685.65 (0.00%)	35.29	3.14	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
24	Dr. Agarwals Health Care Ltd.	Q V PT	15,076 Small Cap	475.55 (0.00%)	113.19	7.44	26.38	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
25	IOL Chemicals And Pharmaceuticals Ltd.	Q V+ PT	4,453 Small Cap	152.75 (0.69%)	32.35	2.48	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
26	Sun Pharma Advanced Research Company Ltd.	Q V+ PT	6,974 Small Cap	215.10 (0.09%)	4.49	5.23	49.34	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
27	Panacea Biotec Ltd.	Q V+ PT	2,654 Small Cap	433.30 (0.00%)	N/A	9.3	-8.75	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
28	Nephrocare Health Services Ltd.	Q V+ PT	6,853 Small Cap	680.05 (-0.21%)	N/A	7.19	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
29	Fischer Medical Ventures Ltd.	Q V PT	2,464 Small Cap	38.57 (2.44%)	N/A	7.89	96.10	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
30	Gujarat Kidney And Super Speciality Ltd.	Q V PT	1,004 Small Cap	128.40 (0.78%)	101.45	4.08	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
Prev 1 2 3 4 5 Next

Screens:

AlphaCases Top Rated Stocks Best Nifty Stocks Best Nifty Next Stocks Best Nifty 500 Stocks Best SmallCap Stocks Top BFSI Stocks

Pharma - Today's Top Gainers

Company Name	CMP	Price Change(%)
Fischer Medical	38.57	2.44%
KMC Speciality Hosp.	133	1.95%
Blue Jet Healthcare	585.45	1.61%
Max Healthcare Inst.	1,129.05	1.30%
Syngene Internatl.	418.85	1.18%

Pharma - Today's Top Losers

Company Name	CMP	Price Change(%)
Nectar Lifesciences	10.06	-3.45%
Fermenta Biotech	433	-2.48%
Themis Medicare	106.45	-1.48%
Wanbury	326.50	-1.42%
Bliss GVS Pharma	455	-1.30%

News about Top Pharma Companies in India

Jul, 2026

Aurobindo Pharma moves up on entering into non-exclusive voluntary licensing agreement with MSD

Aurobindo Pharma is among a select group of global generic manufacturers to have signed this agreement

Jul, 2026

Aurobindo Pharma enters into non-exclusive voluntary licensing agreement with MSD

Aurobindo Pharma is among a select group of global generic manufacturers to have signed this agreement

Jul, 2026

Laurus Labs - Quaterly Results

The company witnessed a 22.64% growth in the revenue at Rs. 17571.60 millions for the quarter ended June 2026 as compared to Rs. 14327.50 millions during the year-ago period.Profit for the quarter ended June 2026 rises by 83.59% to Rs. 2899.60 millions from Rs. 1579.40 millions.Operating profit for the quarter ended June 2026 rose to 5191.30 millions as compared to 3489.00 millions of corresponding quarter ended June 2025.

(Rs. in Million)

	Quarter ended			Year to Date			Year ended
	202606	202506	% Var	202606	202506	% Var	202603	202503	% Var
Sales	17571.60	14327.50	22.64	17571.60	14327.50	22.64	60890.70	52169.80	16.72
Other Income	200.70	215.20	-6.74	200.70	215.20	-6.74	774.30	1004.70	-22.93
PBIDT	5191.30	3489.00	48.79	5191.30	3489.00	48.79	15156.90	10448.00	45.07
Interest	352.00	438.90	-19.80	352.00	438.90	-19.80	1429.60	1822.00	-21.54
PBDT	4839.30	3050.10	58.66	4839.30	3050.10	58.66	13727.30	8626.00	59.14
Depreciation	957.60	935.70	2.34	957.60	935.70	2.34	3786.40	3587.90	5.53
PBT	3881.70	2114.40	83.58	3881.70	2114.40	83.58	9940.90	5038.10	97.31
TAX	982.10	535.00	83.57	982.10	535.00	83.57	2536.10	1234.20	105.49
Deferred Tax	-50.40	-61.60	-18.18	-50.40	-61.60	-18.18	-315.10	-304.20	3.58
PAT	2899.60	1579.40	83.59	2899.60	1579.40	83.59	7404.80	3803.90	94.66
Equity	1080.50	1079.60	0.08	1080.50	1079.60	0.08	1079.70	1078.50	0.11
PBIDTM(%)	29.54	24.35	21.32	29.54	24.35	21.32	24.89	20.03	24.29

Jul, 2026

Onesource Specialty - Quaterly Results

A decent increase of about 39.08% in the sales to Rs. 4464.71 millions was observed for the quarter ended June 2026. The sales figure stood at Rs. 3210.12 millions during the year-ago period.The company almost doubled its revenue to Rs. 512.25 millions from Rs. 248.15 millions in the quarter ended June 2026.Operating Profit saw a handsome growth to 1179.19 millions from 851.30 millions in the quarter ended June 2026.

(Rs. in Million)

	Quarter ended			Year to Date			Year ended
	202606	202506	% Var	202606	202506	% Var	202603	202503	% Var
Sales	4464.71	3210.12	39.08	4464.71	3210.12	39.08	14053.81	12995.89	8.14
Other Income	37.87	52.55	-27.94	37.87	52.55	-27.94	150.08	176.82	-15.12
PBIDT	1179.19	851.30	38.52	1179.19	851.30	38.52	2840.01	3869.57	-26.61
Interest	305.17	270.31	12.90	305.17	270.31	12.90	1205.76	1616.50	-25.41
PBDT	874.02	580.99	50.44	874.02	580.99	50.44	1580.05	1130.57	39.76
Depreciation	361.77	332.84	8.69	361.77	332.84	8.69	1367.95	1345.12	1.70
PBT	512.25	248.15	106.43	512.25	248.15	106.43	212.10	-214.55	-198.86
TAX	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-414.55	0.00
Deferred Tax	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-414.55	0.00
PAT	512.25	248.15	106.43	512.25	248.15	106.43	212.10	200.00	6.05
Equity	114.64	114.46	0.16	114.64	114.46	0.16	114.62	114.43	0.17
PBIDTM(%)	26.41	26.52	-0.41	26.41	26.52	-0.41	20.21	29.78	-32.13

Jul, 2026

Panacea Biotec informs about disclosure

Pursuant to Regulation 30 read with Para B of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘SEBI LODR Regulations’), Panacea Biotec has informed that the Company’s wholly owned subsidiary, Panacea Biotec Pharma (‘PBPL’), has received a Show Cause Notice dated July 23, 2026, from the office of the Assistant Commissioner, Goods and Services Tax (‘GST’), Delhi under Section 73 of Delhi Goods & Services Tax / Central Goods & Services Tax Act & Rules, 2017 alleging total tax liability of ?4.06 Crore including interest, tax and penalty, on account of alleged excess claim of Input Tax Credit in the Annual Return filed for the Financial Year 2022-23. The requisite details as required under Regulation 30 of the SEBI LODR Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, and Industry Standards on Regulation 30 of SEBI LODR Regulations, are annexed as Annexure A.

The above information is a part of company’s filings submitted to BSE.

Jul, 2026

Solara Active Pharma - Quaterly Results

The revenue zoomed 19.57% to Rs. 3816.00 millions for the quarter ended June 2026 as compared to Rs. 3191.50 millions during the corresponding quarter last year.Profit for the quarter ended June 2026 rises by 61.35% to Rs. 169.90 millions from Rs. 105.30 millions.OP of the company witnessed a marginal growth to 639.30 millions from 580.10 millions in the same quarter last year.

(Rs. in Million)

	Quarter ended			Year to Date			Year ended
	202606	202506	% Var	202606	202506	% Var	202603	202503	% Var
Sales	3816.00	3191.50	19.57	3816.00	3191.50	19.57	13689.80	12837.60	6.64
Other Income	19.20	9.80	95.92	19.20	9.80	95.92	58.90	91.40	-35.56
PBIDT	639.30	580.10	10.21	639.30	580.10	10.21	1925.70	2129.80	-9.58
Interest	202.30	239.00	-15.36	202.30	239.00	-15.36	942.40	1148.10	-17.92
PBDT	437.00	341.10	28.11	437.00	341.10	28.11	924.40	981.70	-5.84
Depreciation	267.10	235.80	13.27	267.10	235.80	13.27	996.80	992.50	0.43
PBT	169.90	105.30	61.35	169.90	105.30	61.35	-72.40	-10.80	570.37
TAX	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Deferred Tax	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
PAT	169.90	105.30	61.35	169.90	105.30	61.35	-72.40	-10.80	570.37
Equity	480.60	443.40	8.39	480.60	443.40	8.39	445.10	402.50	10.58
PBIDTM(%)	16.75	18.18	-7.83	16.75	18.18	-7.83	14.07	16.59	-15.21

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2026.

Rank	Company	Market Capitalization 2026 (INR crores)
1	Nectar Lifesciences Ltd.	202 Crore
2	Health X Platform Ltd.	985 Crore
3	Indoco Remedies Ltd.	2,287 Crore
4	Unichem Laboratories Ltd.	3,826 Crore
5	Solara Active Pharma Sciences Ltd.	2,439 Crore
6	Suraksha Diagnostic Ltd.	1,300 Crore
7	Jubilant Pharmova Ltd.	15,582 Crore
8	Dishman Carbogen Amcis Ltd.	2,922 Crore
9	Biocon Ltd.	71,063 Crore
10	Shilpa Medicare Ltd.	12,144 Crore

Do you know? Asking 3 Right Questions minimizes the RISK of Stock Investing To Know

Right Stock | Right Price | Right Allocation

Find best stocks to buy now Find best pharma stocks to buy now

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

You can use different criterias to arrive at the list of best stocks in the Nifty Pharma company index. You can use return ratios like ROCE or ROE, that will help you choose companies with profitable growth.

Based on ROE, the best stocks in the Nifty Pharma companies index are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	ROE
Abbott India Ltd. (M)	Very Good	27,813	59,102	38.08	12.45	26.07	34.24
Torrent Pharmaceuticals Ltd. (L)	Very Good	5,017	1,90,832	88.21	22.69	45.79	29.04
Lupin Ltd. (M)	Somewhat Good	2,424	1,10,189	20.66	4.92	11.95	26.43
Ajanta Pharma Ltd. (M)	Very Good	3,385	42,278	40.04	9.35	27.05	25.35
Alkem Laboratories Ltd. (M)	Very Good	5,600	67,124	30.72	4.80	22.28	17.86

Based on the past year's gain, the best performing stocks are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	Yearly gain (%)
Laurus Labs Ltd. (M)	Very Good	1,714	92,623	105
Sai Life Sciences Ltd. (S)	Very Good	1,283	27,347	53.73
Torrent Pharmaceuticals Ltd. (L)	Very Good	5,017	1,90,832	39.27
Aurobindo Pharma Ltd. (M)	Very Good	1,543	89,115	38.01
Lupin Ltd. (M)	Somewhat Good	2,424	1,10,189	23.52
				View More

Stocks with the highest revenue growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Sales Growth (%)
Sai Life Sciences Ltd. (S)	Very Good	1,283	27,347	80.08	10.90	42.11	17.75
Ajanta Pharma Ltd. (M)	Very Good	3,385	42,278	40.04	9.35	27.05	13.54
Mankind Pharma Ltd. (M)	Very Good	2,570	1,05,357	51.71	6.44	32.38	13.54
Zydus Lifesciences Ltd. (M)	Very Good	1,106	1,10,523	21.93	4.25	13.45	13.52
Lupin Ltd. (M)	Somewhat Good	2,424	1,10,189	20.66	4.92	11.95	13.02

Stocks with high profit growth often witness their stock prices gaining, irrespective of the market movements.

Stocks with the highest profit growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Profit Growth (%)
Lupin Ltd. (M)	Somewhat Good	2,424	1,10,189	20.66	4.92	11.95	32.37
Abbott India Ltd. (M)	Very Good	27,813	59,102	38.08	12.45	26.07	17.33
Dr. Reddys Laboratories Ltd. (M)	Very Good	1,147	96,063	29.81	2.52	15.31	15.75
Zydus Lifesciences Ltd. (M)	Very Good	1,106	1,10,523	21.93	4.25	13.45	14.72
Sun Pharmaceutical Industries Ltd. (L)	Very Good	1,988	4,73,509	41.25	5.67	23.65	14.41

You have 8 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now

Create stable, long-term investment portfolio with strong, consistent stocks.

Start Research-backed Investing ...Now. Subscribe to Sapphire

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Fiduciary-first advisory model.
As SEBI-registered IAs, we are legally and ethically bound to act in the best interests of our clients. We do not sell or distribute any financial products. This ensures our guidance is 100% unbiased and conflict-free.
Deep fundamental research + robust valuation discipline.
Built on more than 15 years of equity research, our framework combines quality assessment, intrinsic value estimation, and a sensible margin-of-safety approach.
Process—not predictions.
We don’t rely on guesswork or market timing. Instead, we focus on asset allocation, risk management, and long-term compounding.
Technology + Human Intelligence.
We believe a combination of both is essential for investing success. We constantly innovate and upgrade in-house tools, financial X-rays, and portfolio analytics so that our team of analysts and advisors are equipped with the best.
Partner with Clients.
We follow a DIWM (Do-It-With-Me) approach where we partner clients in setting goals, financial planning, educating on our investing process and share decision-enabling resources transparently with our clients who retain control on execution.

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

Investing in stocks, mutual funds, debt, and gold
Quality-at-Reasonable-Price way of investing in stocks
Constructing Direct Stock Portfolios with Core, Booster, and Amplifier stocks
A Mutual Fund Portfolio that delivers consistent out-performance and meaningful diversification (low overlap)
Periodic review and rebalancing
Clear Buy-Sell-Hold, and Position-sizing frameworks

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Top Pharma Companies in India by Market Cap

News about Top Pharma Companies in India

Aurobindo Pharma moves up on entering into non-exclusive voluntary licensing agreement with MSD

Aurobindo Pharma enters into non-exclusive voluntary licensing agreement with MSD

Laurus Labs - Quaterly Results

Onesource Specialty - Quaterly Results

Panacea Biotec informs about disclosure

Solara Active Pharma - Quaterly Results

Publicly traded pharmaceuticals

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2026.

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

How to select the top Nifty Pharma stocks based on RoE?

What are the best-performing stocks in the Nifty Pharma index?

Which Nifty Pharma stocks have the highest revenue growth in the past five years?

Which Nifty Pharma stocks had the highest profit growth in the past five years ?

Create stable, long-term investment portfolio with strong, consistent stocks.

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.